Year: 2023

Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA Fast Track designation in August Part 1 data recently presented at the North American Cystic Fibrosis Conference (NACFC) CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023. “Thanks to the continued execution of our clinical team, we are now analyzing data from Part 2 of the Phase 1b/2a trial of BX004 and expect to announce the results later this month,” said Jonathan Solomon, Chief...

Quarterly revenue of $17.0 million including $4.5 million from the high performance computing business 9,366 self-mined Bitcoin held in custody or pledged as collateral on September 30 TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Hut 8 Mining Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), one of North America’s largest, innovation-focused digital asset mining pioneers, and high performance computing infrastructure provider, announced its financial results for the quarter ended September 30, 2023 (“Q3 2023”). All dollar figures are in Canadian Dollars (“CAD”), unless otherwise stated. “Our team continued to be laser-focused on closing our merger with USBTC in the third quarter, and made material progress in achieving key milestones, including securing shareholder approval of the merger and obtaining...

Quarterly revenue of $17.0 million including $4.5 million from the high performance computing business 9,366 self-mined Bitcoin held in custody or pledged as collateral on September 30 TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Hut 8 Mining Corp. (Nasdaq | TSX: HUT) (“Hut 8” or the “Company”), one of North America’s largest, innovation-focused digital asset mining pioneers, and high performance computing infrastructure provider, announced its financial results for the quarter ended September 30, 2023 (“Q3 2023”). All dollar figures are in Canadian Dollars (“CAD”), unless otherwise stated. “Our team continued to be laser-focused on closing our merger with USBTC in the third quarter, and made material progress in achieving key milestones, including securing shareholder approval of the merger and obtaining...

Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024. Acimtamig: Received fast-track designation for the combination of acimtamig and AlloNK®. LuminICE-203: Received encouraging feedback from the FDA on Type C meeting. AFM13-104: Oral presentation of updated data of acimtamig in combination with cord blood-derived NK cells at the American Society of Hematology (ASH) 2023 Annual Meeting. AFM24 combination with atezolizumab: On track to report data from three expansion cohorts in December 2023. AFM28: Cleared third dose cohort without dose limiting toxicities; completed enrollment in the fourth cohort. Cash runway into 2025: As of September 30, 2023, cash, cash equivalents and financial assets were €97.5 million.MANNHEIM, Germany, Nov....

Tuesday, Schouw & Co. released its interim report for the third quarter of 2023; This was a very good third quarter with a significant revenue improvement. Reported EBITDA improved by relatively more than revenue, which had not been expected. Cash flows from operations for the quarter sharply improved. HighlightsRevenue up by 15% for the quarter to DKK 10.5bn EBITDA up by 34% to DKK 909m Strong cash flows from operations of DKK 1,490m ROIC excluding goodwill improved to 12.4% Full-year EBITDA guidance raised.Statement by Jens Bjerg Sørensen, President of Schouw & Co. – The third quarter were in many ways the best ever in Schouw & Co.’s 145-year history. We delivered both revenue and EBITDA at an all-time high, and the companies of the Schouw & Co. Group performed very well across the board and in several respects...

Third Quarter 2023 HighlightsRevenue of $336.3 million increased by 13.1% compared to the prior year quarter. Successfully transitioned to a publicly traded company with the completion of our business combination with Digital Transformation Opportunities Corp. Expanded into Florida market with Florida Oncology & Hematology Expanded into urology market with Triple Crown Urology in Arkansas Added 19 new providers to the AON platformFORT MYERS, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) — American Oncology Network, Inc. (NASDAQ: AONC), a leading oncology platform with an innovative model of physician-led, community-based oncology management, today announced financial results for the three-month (“Third Quarter 2023”) and nine-month periods (“Year-to-Date 2023”) ended September 30, 2023. Todd Schonherz, AONC chief executive officer,...

WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. “Building off of our positive corporate update, and with nearly $400 million in cash, cash equivalents and marketable securities as of September 30th of this year, ProKidney continues to be well capitalized to continue executing on both of our Phase 2 and Phase 3 trials in high-risk CKD patients in need,” said James Coulston, Chief Financial Officer at ProKidney. “With cash expected to fund operations into the fourth quarter of 2025 and interim data readouts for REGEN-007 during that period, we remain well capitalized to continue executing on our development...